Skip to contentS
Sigyn Therapeutics, Inc.
S
SIGYSigyn Therapeutics, Inc. Q3 2018 · 10-Q
Revenue$90.45K$90.45K−64.7% vs Q3 2017 Net Income-$355.99K-$355.99KN/M vs Q3 2017 EPS Diluted-$0.01-$0.01N/M vs Q3 2017 Gross Profit$77,791−50.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
Operating Cash Flowderived$29,917+1,330.8% Margins · derivedGross margin86.0%+24.5 pt vs Q3 2017
Operating margin-297.1%−70.5 pt vs Q3 2017
Net margin-393.6%+191.5 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 14, 2018 · 45 d after period end